Phuturdex › Diseases › Depression
Drugs in development · updated 30 October 2026
Depression: drugs in development
As of 30 October 2026 there are 124 active clinical trials (recruiting or ongoing, phases I–III) on 73 drugs for depression. 32 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PsilocybinPsilocybine | III | 31 | NCT07226232 |
| OsavampatorNBI-1065845 | III | 4 | NCT06911112 |
| AzetukalnerXEN1101 | III | 3 | NCT07076407 |
| CYB003 | III | 3 | NCT06793397 |
| Brenipatide | III | 2 | NCT07775300 |
| NRX-101 | II–III | 2 | NCT07227103 |
| Ozone | II–III | 2 | NCT06799351 |
| Creatine Monohydrate | III | 1 | NCT02568878 |
| LPCN 1154A | III | 1 | NCT07822321 |
| MelatoninSlenyto®, Circadin® | II–III | 1 | NCT05474846 |
| Pregnenolone | I–II | 3 | NCT07685964 |
| DT-101 | II | 2 | NCT07610473 |
| SPT-300 | II | 2 | NCT07161700 |
| AFA-281 | II | 1 | NCT06710431 |
| Allopregnanolone | II | 1 | NCT04003285 |
| Apimostinel Infusion | II | 1 | NCT06400121 |
| BMS-986511 | II | 1 | NCT07772531 |
| CI-581a | II | 1 | NCT05690503 |
| CI-581b | II | 1 | NCT05690503 |
| ELE-101 | I–II | 1 | NCT05434156 |
| Hydroxynorketamine | II | 1 | NCT06511908 |
| Lysergic Acid Diethylamide Tartrate | II | 1 | NCT05883540 |
| OSU6162 | II | 1 | NCT05641623 |
| Psilocyn | I–II | 1 | NCT06898606 |
| RE104 for Injection | II | 1 | NCT07002034 |
| Vitamin B6 | II | 1 | NCT05837104 |
| 11C-PS13 | I | 1 | NCT04582916 |
| 18F-PF-06445974 | I | 1 | NCT05703685 |
| D-Serine | I | 1 | NCT06876129 |
| Duavive | I | 1 | NCT04478305 |
| Ketamin | I | 1 | NCT06698848 |
| Visbiome | Early I | 1 | NCT06898788 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| KetamineKetalar® | III | 19 | NCT06781697 |
| SertralineZoloft® | II–III | 4 | NCT07574060 |
| EsketamineSpravato | III | 2 | NCT06713616 |
| MethylphenidateConcerta, Relexxii® | II–III | 2 | NCT05474846 |
| Oxytocin nasal sprayOxytocin 10 Usp Units In Dextrose 5%®, Oxytocin 5 Usp Units In Dextrose 5%® | II–III | 2 | NCT06248710 |
| AllopurinolAloprim®, Lopurin® | II–III | 1 | NCT07574060 |
| BuprenorphineBrixadi®, Sublocade® | III | 1 | NCT03646058 |
| CannabidiolEpidiolex, Epidyolex® | III | 1 | NCT05867849 |
| CariprazineVraylar, Hydrochloride Carliprazine capsules | III | 1 | NCT04777357 |
| LumateperoneCaplyta® | III | 1 | NCT07623135 |
| MorphineArymo Er®, Morphabond Er® | III | 1 | NCT06835504 |
| N-AcetylcysteineAcetylcysteine, Acetadote | III | 1 | NCT07464886 |
| D-CycloserineCycloserine | I–II | 4 | NCT07593222 |
| FluoxetineSarafem®, Prozac Weekly® | I–II | 3 | NCT06898606 |
| BaricitinibOlumiant® | II | 2 | NCT07608796 |
Sorted by most advanced phase and number of active trials. Showing 15 of 41 drugs.
All 73 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Mental disorder 24 drugs
- Mood disorder 8 drugs
- Depressive disorder 12 drugs
- Nervous System Diseases 39 drugs
- Neurologic Manifestations 15 drugs
- Central nervous system disease 38 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003863 “Depression”.